Saltar al contenido
Merck
Todas las fotos(1)

Documentos

47639

Sigma-Aldrich

Fmoc-His(Trt)-OH

≥98.0% (sum of enantiomers, HPLC), for peptide synthesis

Sinónimos:

Nα-Fmoc-N(im)-trityl-L-histidine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C40H33N3O4
Número de CAS:
109425-51-6
Peso molecular:
619.71
Beilstein/REAXYS Number:
5204720
MDL number:
MFCD00043332
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
57651056
NACRES:
NA.26

product name

Fmoc-His(Trt)-OH, ≥98.0% (sum of enantiomers, HPLC)

assay

≥98.0% (sum of enantiomers, HPLC)

optical activity

[α]/D 87±5°, c = 1 in chloroform

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

application(s)

peptide synthesis

functional group

Fmoc

storage temp.

2-8°C

SMILES string

OC(=O)[C@H](Cc1cn(cn1)C(c2ccccc2)(c3ccccc3)c4ccccc4)NC(=O)OCC5c6ccccc6-c7ccccc57

InChI

1S/C40H33N3O4/c44-38(45)37(42-39(46)47-26-36-34-22-12-10-20-32(34)33-21-11-13-23-35(33)36)24-31-25-43(27-41-31)40(28-14-4-1-5-15-28,29-16-6-2-7-17-29)30-18-8-3-9-19-30/h1-23,25,27,36-37H,24,26H2,(H,42,46)(H,44,45)/t37-/m0/s1

InChI key

XXMYDXUIZKNHDT-QNGWXLTQSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Fmoc-His(Trt)-OH can be used as a building block in solid-phase peptide synthesis (SPPS).

Analysis Note

may contain ~1 equivalent solvent

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 5

1 of 5

Fmoc-Arg(Pbf)-OH ≥98.0% (HPLC)

Sigma-Aldrich

47349

Fmoc-Arg(Pbf)-OH

Fmoc-Gly-OH ≥98.0% (T)

Sigma-Aldrich

47627

Fmoc-Gly-OH

Fmoc-Lys(Boc)-OH ≥98.0% (HPLC)

Sigma-Aldrich

47624

Fmoc-Lys(Boc)-OH

Fmoc-Ile-OH ≥98.0% (T)

Sigma-Aldrich

47628

Fmoc-Ile-OH

Fmoc-Met-OH ≥98.0% (HPLC)

Sigma-Aldrich

47634

Fmoc-Met-OH

Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery
Malamas AS, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 171(3), 296-307 (2013)
Yoonhee Bae et al.
International journal of pharmaceutics, 515(1-2), 186-200 (2016-11-05)
Glioblastoma multiform (GBM) is the most frequent and aggressive form of brain tumors in adults. However, the development of more efficient and safe nonviral vector gene therapy represents a promising therapeutic approach, using a tumor-specific killer gene, named apoptin. In
Yoonhee Bae et al.
Journal of pharmaceutical sciences, 106(6), 1618-1633 (2017-02-12)
Malignant glioma is the most common and aggressive form of primary brain tumor in adults. In this study, we describe the efficacy of nonviral gene delivery carriers, histidine- and arginine- or histidine- and lysine-grafted polyamidoamine (PAMAM) dendrimers (PAMAM-H-R and PAMAM-H-K)
Tsukasa Mizutaru et al.
ACS applied materials & interfaces, 9(11), 9996-10002 (2017-03-11)
For exerting potential catalytic and photocatalytic activities of metal nanoparticles (MNPs), immobilization of MNPs on a support medium in highly dispersed state is desired. In this Research Article, we demonstrated that surfactant-free platinum nanoparticles (PtNPs) were efficiently immobilized on graphene
Petro P Czupiel et al.
Journal of controlled release : official journal of the Controlled Release Society, 305, 210-219 (2019-05-10)
Currently, there are limited treatment options for multi-drug resistant breast cancer. Lipid-modified cationic peptides have the potential to reach the mitochondria, which are attractive targets for the treatment of multi-drug resistant (MDR) breast cancer; yet, little is known about their
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico